Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Feb 25, 2019

Sanofi and Regeneron strongly disagree with verdict upholding three of five Amgen U.S. patent claims relating to PCSK9 antibodies

Praluent® (alirocumab) continues to be available in the U.S.
Feb 25, 2019

Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
Feb 13, 2019

Provention Bio To Present at 8th Annual Leerink Partners Global Healthcare Conference
Feb 11, 2019

Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price

* This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients
Feb 7, 2019

Sanofi delivers 2018 business EPS growth of 5.1% at CER
- Video 1
- Photos 4

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.